Hemodynamic stability is an important goal of patient management in anesthesia. Therefore, we studied the hypothesis that a BIS-guided manual administration compared to a weight-related manual administration of propofol would reduce the incidence of arterial hypotension during induction of general anesthesia.
Results of our study could not confirm this hypothesis. In addition, all other secondary outcome parameters we used to examine the hypotensive effects of propofol were similar in both study groups. Results of a post-hoc analysis using systolic blood pressure as an alternative endpoint with a pressure < 80 mmHG as a threshold to define hypotension could not confirm our hypothesis either. Interestingly, there was even a trend for patients in the BIS group to have a higher incidence of hypotension with the drop in blood pressure being more pronounced (Additional file 4: Table S2B).
Hypertension and Tachycardia were observed less frequently in the BIS group. Whether a BIS-guided induction could prevent hypertension and tachycardia needs to be studied in a future trial as these events were only secondary endpoints in our study.
To date, this is the first clinical trial to study if a manually-titrated, BIS-guided vs. a weight-related administration of propofol can reduce arterial hypotension. The rationale for this study is based on the idea that arterial hypotension which is frequently observed during induction of general anesthesia with propofol might be caused to some degree by an individual overdose and that the use of BIS monitoring allows for administration of propofol tailored to its hypnotic effects in individual patients which could prevent the administration of an overdose.
The sensitivity of an individual patient to the hypnotic effects of propofol varies. In the first place it depends on body weight as reflected by the common practice of a weight-related administration. Studies also unequivocally demonstrated that age is another important factor in this respect with elderly patients needing less propofol than young patients [19, 20]. Results of these dose finding studies were confirmed by results of our linear regression analysis demonstrating that age was the strongest predictor of drop in MAP compared to all variables tested. Both pharmacodynamic and pharmacokinetic reasons account for the age-dependent sensitivity to propofol [21, 22]. These include a lower initial distribution volume (volume of the central compartment) resulting in higher propofol concentrations right after injection [23] and a decrease in cardiac output in elderly patients [24]. The latter is underpinned by studies which have demonstrated an inverse relationship between cardiac output and plasma propofol concentrations [25, 26]. Accordingly, cardiac diseases that go along with a reduced cardiac output are of particular importance for patient’s sensitivity to propofol during induction. This observation is confirmed by results of a very recent study comparing the efficacy of anesthetic depth control using closed-loop vs. TCI administration of propofol guided by BIS in predominantly non-geriatric patients with an average ejection fraction < 40% [27]. Unlike age and cardiac function, the role of gender concerning patient’s sensitivity to propofol is less clear [28, 29]. Given the various factors that have an impact on patient’s sensitivity to propofol, it is impossible to predict the exact requirement of a patient for propofol. By analogy, it is conceivable that some patients who are administered propofol by weight are administered an overdose which intensifies the depressant effects of propofol to the cardiovascular system given propofol’s hypotensive effects were demonstrated to be dose dependent [1, 2].
Earlier studies that investigated the dose requirements and the side effects of propofol used clinical endpoints such as loss of consciousness or loss of eye lash reflex [19, 30, 31]. Using a clinical endpoint such as loss of consciousness clearly allows detecting the minimal dose of any drug with hypnotic effects. However, it does not rule out an overdose as any deeper levels of anesthesia cannot be detected with this endpoint. On the contrary, use of an electroencephalogram (EEG)-derived depth of anesthesia monitor enables to detect an overdose and more importantly in this context the extent of an overdose. BIS indices have been shown to correlate with propofol target concentrations and the level of sedation produced by propofol and to accurately predict loss of consciousness [12, 13, 32, 33]. Consistent with these results, BIS has been applied successfully as a target parameter to guide induction and maintenance of general anesthesia both using closed-loop delivery and manually controlled administration of propofol [34].
Accordingly, use of the BIS-monitor facilitates the individual titration of propofol to a desired hypnotic level and thereby might reduce the incidence and extent of unintended side-effects such as arterial hypotension. However, so far, no study has been published confirming this assumption by comparing the effects of a manually controlled BIS-guided to a weight-based administration of propofol on blood pressure during induction. In contrast, a study comparing closed-loop controlled administration of propofol using bispectral index as the controlled variable with manually controlled administration of propofol found that the maximal drop in blood pressure during induction was more pronounced in patients who were manually given propofol [35]. The unavailability of commercially available medical devices that are certified for use in patients constitutes, however, a massive barrier which impedes the closed loop technology to be implemented in daily clinical practice. It was, therefore, our intention to study our hypothesis with certified devices that have a CE mark and that are used in everyday clinical practice.
In our study the patients belonging to the BIS group were administered an initial bolus of 1.5 mg/kg followed by increments of 20 mg until BIS index was < 61. This regimen resulted in similar doses of propofol administered to both study groups consistent with similar BIS indices in both study groups. We chose to administer 1.5 mg/kg as an initial bolus as this is the lower limit of the dose recommended for induction of general anesthesia (1.5–2.5 mg/kg) by the manufacturer. This is in accordance with an early study using a clinical endpoint (unconsciousness detected by loss of verbal contact with the patient) to identify the smallest effective doses of propofol for induction [19]. An initial bolus of 1.5 mg/kg is also consistent with results of a very recent multicenter trial comparing the feasibility and efficacy of an automated (closed-loop) to a manual BIS-guided administration of propofol under similar conditions (non-geriatric patients, 2 μg/kg fentanyl prior to propofol) [36]. Median [IQR] propofol induction doses in the closed-loop and the manual group were 1.4 (1.2–1.8) and 1.8 (1.6–2.2), respectively. In this context it is important to note that these patients had been given lorazepam 1–2 mg orally as premedication while patients of our study had not been given any sedatives prior to induction. In accordance with an initial bolus of 1.5 mg/ kg were findings of another very recent clinical trial that also studied propofol requirements in unpremedicated non-geriatric patients [37]. Mean required propofol doses (95% confidence intervals) during closed-loop anesthesia induction were 2.06 mg/kg (1.68–2.43) in the hypnosis group vs. 1.79 mg/kg (1.54–2.03) in the non-hypnosis group. In contrast, an initial bolus of 1.5 mg/kg is inconsistent with findings of a prospective cohort comparison between non-geriatric obese and lean patients using a BIS-guided closed-loop co-administration of propofol and remifentanil [38]. Median (IQR) propofol induction dose in unpremedicated obese and lean patients were 1.2 (1.1–1.6) and 1.3 (1.0–1.7), respectively. Results of that latter study suggest that 1.5 mg/kg as an initial bolus in the BIS group might have led to administering similar induction doses in both groups of this study.
Interestingly, results of this study demonstrated that no clear-cut linear correlations between MAP and BIS following administration of propofol exist suggesting that arterial hypotension in the observed range is not associated with low BIS-indices. These findings are consistent with results of another study which demonstrated that lower BIS values in patients administered propofol manually guided by BIS compared to BIS-guided closed-loop administration of propofol were not associated with different minimal MAP between study groups [36]. Accordingly, results of our study also suggest that the use of a BIS monitor and probably any other EEG-based monitor to titrate administration of propofol to an adequate level of anesthesia does not significantly reduce the incidence and degree of arterial hypotension in non-geriatric patients.
This conclusion is consistent with results of a recent clinical trial in which the hemodynamic effects of a manual BIS-guided induction of anesthesia with propofol compared to etomidate were studied [39]. Despite the BIS-guided protocol, 8 out of 23 patients (35%) given propofol for induction had arterial hypotension defined as a MAP < 55 mmHg. Interestingly, the incidence of hypotension observed in that study is similar to the one seen in the present study despite a lower mean dose of propofol (1.14 mg/kg vs. 1.93 mg/kg) and a much lower infusion rate (0.5 mg/kg/min vs. 130 mg/min). Lower infusion rates have consistently been shown to be associated with reduced dose requirements and prolonged induction times [19, 31, 40,41,42]. However, results of previous clinical trials which didn’t use BIS to guide administration of propofol to study the impact of infusion rates of propofol on arterial blood pressure have been inconsistent [19, 30, 31, 40,41,42,43]. In this context, a very recent study in non-geriatric patients evaluating the feasibility and efficacy of automated versus manually controlled BIS-guided induction with propofol is remarkable [36]. Results of that study showed that different infusion rates (approximately 30 mg/min vs 60 mg/min) did not result in a different minimal MAP during induction suggesting that propofol infusion rates for induction of anesthesia may not have a substantial impact on arterial blood pressure in non-geriatric patients. Considering the uncertainty about the impact of speed of injection on decrease in arterial blood pressure, in this study propofol was infused at the same rate (130 mg/min) in both groups.
The prevention of arterial hypotension is of particular relevance to anesthetic care given the negative effects arterial hypotension may have on patient outcome. A case-control study conducted among 48,241 patients showed a significant association between intraoperative hypotension and the risk of a postoperative stroke within 10 days after surgery [9]. More recently, results of a retrospective analysis in 33,330 patients undergoing non-cardiac surgery indicated that even a short duration (< 5 min) of a MAP < 55 mmHg is associated with an increased risk for both AKI and myocardial injury [10]. Therefore, even short lasting periods of arterial hypotension that frequently occur following induction of general anesthesia with propofol should be avoided.
This study has several limitations related to 1) the drop-outs, 2) the bispectral index, and 3) the study protocol.
1) There were 5 drop-outs who all belonged to the NON-BIS group. A post hoc sensitivity analysis considering all 5 patients to have the lowest MAP at the different time points showed that the severe hypotension rate was significantly higher in the NON-BIS group and that there was a trend for the hypotension rate to be significantly higher in the NON-BIS group (Additional file 5: Table S2C).
2) All devices using processed EEG including BIS have various limitations inherent to their technology [14] which can result in incorrectly assessing the depth of anesthesia. We chose a target range of 40–60 in accordance with the recommendations of the manufacturer, the results of studies examining propofol requirements for induction and maintenance [35, 44], and the findings of trials investigating the efficacy of BIS to prevent awareness [45]. While the upper threshold is supported by good evidence, this is not the case for the lower limit (BIS < 40) which we used to define an overdose. Accordingly, we cannot rule out that for some patients a BIS < 45 or even < 50 would have been the correct individual threshold to define an overdose. However, results of our study presented in Fig. 4 indicate that a higher threshold wouldn’t have produced a different result concerning the similarities between both study groups with respect to drop in bispectral indices.
3) BIS indices plotted over time showed that the overall distribution of BIS-indices including those < 40, < 45 and < 50 were similar in both groups consistent with similar doses of propofol administered to patients of both groups. This means that the administration of propofol in the BIS-group consisting of an initial 1.5 mg/kg bolus followed by 20 mg boluses with a 20 s wait in between each administration of propofol until BIS was < 61 did not result in patients in the BIS-group being administered lower doses of propofol and thereby having a lower incidence of overdose when using a BIS < 40 as a threshold for propofol overdose.
We chose to stop the injection of propofol once BIS was < 61 as did Möller Petrun and Kamenik in their study [39]. There is a time delay between injection of the hypnotic and decrease in BIS index which results from drug transition time (from injection site to effect site) and from index calculation time. Using simulated signals, the latter was shown for decreasing BIS indices (from 98 down to 52) to be 14 s [46]. Adding another few seconds for drug transition, 20 s wait in between propofol injections were considered by us to be sufficient to avoid overdosing propofol. However, considering the huge variability in time delay observed with smaller decreasing BIS-indices (decrease of 11 or 12 index points) ranging from 15 to 66 s [46], 20 s wait may have been too short to avoid overdosing propofol in some patients. A longer wait in between the injections was felt unsuitable though for standard anesthetic practice.
For the same reason, a relatively high infusion rate was chosen, as this was shown in many studies to result in faster induction times [19, 30, 31, 40, 41]. High infusion rates compared to low infusion rates result in higher propofol plasma concentrations. Accordingly, the dose of propofol in transit (from the injection site to the effect site) that will cause the BIS to further decrease after stopping administration of propofol is the higher, the faster the speed of injection of propofol. Even though results of studies examining the impact of propofol infusion rates on drop in arterial blood pressure including more recent results of studies that used closed-loop administration with BIS as the target have been inconsistent, we cannot rule out a negative impact of the high infusion rate in our study on arterial hypotension as it was higher than the ones of most other studies [36, 39].
Therefore, a higher target BIS (e.g. 65 instead of 60) combined with a longer wait in between the repetitive propofol injections (e.g. every 30 s instead of every 20 s), a lower infusion rate (e.g. 100 mg/min instead of 130 mg/min), and a smaller initial bolus of propofol (e.g. 1 mg/kg instead of 1.5 mg/kg) and might have resulted in patients of the BIS group to get lower doses of propofol and thereby to have significantly less BIS values < 40 compared to patients in the NON-BIS group.
However, it is important to remember in this context that there was no linear correlation between BIS indices and MAP suggesting that even if neither patient in the BIS group had had a BIS < 40, no significant differences concerning the drop in MAP between the study groups would have been observed.
Participating patients in our study were predominantly non-geriatic and without significant cardiac comorbidity. Given the impact of age and cardiac output on patient’s requirement for propofol it is conceivable that we could have observed lower BIS values and a more pronounced drop in MAP in patients of the NON-BIS group had we carried out the study in geriatric patients with low cardiac output.